Ashwani Patil | Cancer Biology | Best Scholar Award

Dr. Ashwani Patil | Cancer Biology | Best Scholar Award

Assistant Professor, Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research India

Dr. Ashwani Patil is a passionate pharmacologist specializing in neurological disorders and cancer research. He completed his Ph.D. in Pharmacology from the Institute of Chemical Technology (ICT), Mumbai, with a focus on preclinical drug development. His research at Bhabha Atomic Research Centre and NIRRH Mumbai deepened his expertise in molecular mechanisms underlying complex diseases. With hands-on experience in animal handling, molecular techniques, and pharmacological testing, he has contributed significantly to understanding disease pathology and potential therapeutic targets for cancer and neurological disorders.

Professional Profile 

Scopus

Scholar

🎓Education

Ph.D. in Pharmaceutical Tech. (Pharmacology), Institute Of Chemical Technology, Mumbai (2024). M. Pharmacy (Pharmacology), R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur (2018). Bachelor of Pharmacy, A.R.A College of Pharmacy, Dhule (2016)

💼Experience

Junior Research Fellow, R.C. Patel Institute of Pharmaceutical Education and Research, Shirpur (2018-2019). Research Scholar, Institute of Chemical Technology, Mumbai (2022-Present). Assistant Professor, Dr. D Y Patil Institute of Pharmaceutical Science and Research, Pune (2019-2020, 2024). Expertise in preclinical drug studies, rodent surgery, data analysis, and project planning.

🏆Award and Honor

DAE-ICT Fellowship, 2024. 1st Position in Poster Presentation, 7th International Conference on “Emerging Trends in Drug Development and Delivery” (2024). Research Excellence Award, GEU, Dehradun (2015). Best Paper Presentation Award, TriboIndia 2023, NIT Srinagar

🔬 Research Focus

Dr. Patil’s research spans preclinical drug development, focusing on neurological disorders and cancer. His work investigates therapeutic targets, pharmacodynamics, and the molecular mechanisms of disease pathology. Key areas of interest include rodent models, drug efficacy, safety profiles, and mitochondrial toxicity. His publications highlight cancer cell cytotoxicity and cardioprotective effects, contributing to the understanding of pharmacological agents in disease treatment.

Publications Top Noted

1. Title: Cardioprotective effect of CB1 receptor antagonist AM251 against β receptor-stimulated myocardial infarction via modulation of NF-kB signaling pathway in diabetic mice

Year: 2024
Authors: Pawar, H.D., Patil, Y., Patil, A., Ojha, S., Goyal, S.N.
Citation: Heliyon, 10(15), e35138
Citations: 0

2. Title: Mitochondria-targeted derivative of pterostilbene, a dietary phytoestrogen, exhibits superior cancer cell cytotoxicity via mitochondrial superoxide mediated induction of autophagy

Year: 2023
Authors: Ibrahim, M.K., Nandha, S.R., Patil, A.S., Sharma, D., Sandur, S.K.
Citation: Advances in Redox Research, 8, 100071
Citations: 1

3. Title: Mitochondriotropic Derivative of Ethyl Ferulate, a Dietary Phenylpropanoid, Exhibits Enhanced Cytotoxicity in Cancer Cells via Mitochondrial Superoxide-Mediated Activation of JNK and AKT Signalling

Year: 2023
Authors: Patil, A.S., Ibrahim, M.K., Sathaye, S., Sharma, D., Sandur, S.K.
Citation: Applied Biochemistry and Biotechnology, 195(3), 2057–2076
Citations: 2

4. Title: Plant-derived natural therapeutics targeting cannabinoid receptors in metabolic syndrome and its complications: A review

Year: 2020
Authors: Patil, A.S., Mahajan, U.B., Agrawal, Y.O., Sharma, C., Goyal, S.N.
Citation: Biomedicine and Pharmacotherapy, 132, 110889
Citations: 17

5. Title: Protective effect of omeprazole and lansoprazole on β-receptor stimulated myocardial infarction in Wistar rats

Year: 2019
Authors: Patil, A.S., Singh, A.D., Mahajan, U.B., Ojha, S., Goyal, S.N.
Citation: Molecular and Cellular Biochemistry, 456(1-2), 105–113
Citations: 17

 

Somnath Paul | Cancer Immunotherapy | Best Researcher Award

Dr. Somnath Paul | Cancer Immunotherapy | Best Researcher Award

Staff Scientist, Washington University United States

Somnath Paul, Ph.D., is a Staff Scientist in the Department of Pathology and Immunology at Washington University in St. Louis, MO. With a robust academic and research career, he specializes in molecular genetics, epigenetics, and immunology. Over the years, Dr. Paul has contributed significantly to cancer research, developing new strategies for tumor profiling and immunotherapy. He has worked at prestigious institutions like the University of Texas MD Anderson Cancer Center and CSIR-Indian Institute of Chemical Biology, publishing several key research articles.

Profile

Scopus

Scholar

🎓 Education

Dr. Paul earned his Ph.D. in Molecular and Human Genetics from Jadavpur University, India (2016), after completing a Master’s in Genetics at the University of Calcutta (2008). He began his academic journey with a Bachelor’s in Physiology from Presidency College, University of Calcutta (2006). His educational foundation laid the groundwork for his research focus on epigenetics, immunology, and cancer biology.

💼 Experience

Dr. Paul’s professional career spans prestigious institutions, including Washington University (2024–Present), University of Texas MD Anderson Cancer Center (2020–2024), and CSIR-Indian Institute of Chemical Biology (2009–2016). His work focuses on immunotherapy, monoclonal antibody production, and the genetic regulation of cancer. He has been a postdoctoral fellow, research scientist, and project assistant, contributing to several groundbreaking research projects in molecular biology, toxicology, and immunology.

🏆 Awards and Honors

Dr. Paul has received notable accolades, such as the prestigious NIH-funded research project on INO80 chromatin remodeling. He was also honored with research excellence awards, including one from GEU, DDN in 2015, and the Early Career Research Award from SERB (2017). Additionally, he received travel grants from DST (2012) and presented a best paper at TriboIndia-2023 Conference.

🔬 Research Focus

Dr. Paul’s research is primarily centered on understanding tumor progression through circulatory tumor cell profiling, tumor remission and relapse monitoring, and novel monoclonal antibody development for immunotherapy. His work includes studying the infection dynamics of herpes viruses, epigenetic mechanisms of cancer, and identifying biomarkers for early disease detection. He aims to enhance therapeutic strategies through innovative platforms and experimental models.

🏆 Conclusion

Dr. Somnath Paul is a strong contender for the Best Researcher Award due to his robust academic and research portfolio, innovative contributions, and extensive publication record. Addressing the identified areas for improvement could further bolster his candidacy for this and similar accolades in the future.

Publication

  1. Arsenic exposure through drinking water increases the risk of liver and cardiovascular diseases in the population of West Bengal, India
    Year: 2012
    Authors: N Das, S Paul, D Chatterjee, N Banerjee, NS Majumder, N Sarma, TJ Sau, …
    Citations: 150

 

  1. Functional compensation of glutathione S-transferase M1 (GSTM1) null by another GST superfamily member, GSTM2
    Year: 2013
    Authors: P Bhattacharjee, S Paul, M Banerjee, D Patra, P Banerjee, N Ghoshal, …
    Citations: 104

 

  1. Loss of Snf5 Induces Formation of an Aberrant SWI/SNF Complex
    Year: 2017
    Authors: P Sen, J Luo, A Hada, SG Hailu, ML Dechassa, J Persinger, S Brahma, …
    Citations: 99

 

  1. The Arp8 and Arp4 module acts as a DNA sensor controlling INO80 chromatin remodeling
    Year: 2018
    Authors: S Brahma, M Ngubo, S Paul, M Udugama, B Bartholomew
    Citations: 81

 

  1. Arsenic-induced toxicity and carcinogenicity: a two-wave cross-sectional study in arsenicosis individuals in West Bengal, India
    Year: 2012
    Authors: S Paul, N Das, P Bhattacharjee, M Banerjee, JK Das, N Sarma, A Sarkar, …
    Citations: 78

 

  1. Arsenic-induced promoter hypomethylation and over-expression of ERCC2 reduces DNA repair capacity in humans by non-disjunction of the ERCC2/Cdk7 complex
    Year: 2014
    Authors: S Paul, N Banerjee, A Chatterjee, TJ Sau, JK Das, PK Mishra, …
    Citations: 65

 

  1. Recent advances in arsenic research: significance of differential susceptibility and sustainable strategies for mitigation
    Year: 2020
    Authors: T Sanyal, P Bhattacharjee, S Paul, P Bhattacherjee
    Citations: 62

 

  1. Epimutagenesis: A prospective mechanism to remediate arsenic-induced toxicity
    Year: 2015
    Authors: S Paul, AK Giri
    Citations: 52

 

  1. Risk of Occupational exposure to Asbestos, Silicon and Arsenic on Pulmonary Disorders: Understanding the Genetic-Epigenetic Interplay and Future Prospects.
    Year: 2016
    Authors: P Bhattacharjee, S Paul, P Bhattacharjee
    Citations: 47

 

  1. Epigenetic Modifications of DAPK and p16 Genes Contribute to Arsenic-Induced Skin Lesions and Non-Dermatological Health Effects
    Year: 2013
    Authors: N Banerjee, S Paul, TJ Sau, JK Das, A Bandyopadhyay, AK Giri
    Citations: 44

 

 

Di Zhu| Immuno-oncology| Best Researcher Award

Mr. Di Zhu| Immuno-oncology| Best Researcher Award

Professor at Fudan University,  China

Di Zhu is a Professor in the Department of Pharmacology at Fudan University, specializing in immuno-oncology and cancer research. Born on October 13, 1983, he holds a Ph.D. in Biochemistry and Molecular Biology. With over 8 years of academic experience, he has pioneered groundbreaking therapies targeting colorectal cancer. Recognized globally for his contributions to cancer immunotherapy, he combines innovative research with clinical applications to improve patient outcomes.

Profile

Scholar

Education 🎓

Ph.D. in Biochemistry & Molecular Biology (2005–2010), Shanghai Institute of Biochemistry and Cell Biology, CAS. Postdoctoral Fellow (2011–2015), Dana-Farber Cancer Institute, Harvard University. Undergraduate studies at Shandong University, earning accolades like the National Sci. & Tech. Challenge Cup (2004).

Experience 💼

Researcher: Fudan University, School of Basic Medical Sciences (2021–Present). Researcher: Minhang & Zhongshan Hospitals, Fudan University (2017–Present). Researcher: Fudan University, School of Pharmacy (2016–2021). Led 12 projects, supervised 16 research scholars, and organized 5 workshops globally.

Awards and Honors 🏅

Gold Medal: Global Life & Health Technology Concept Validation (2024). Excellence Award: Hai Ju Ying Cai Global Innovation (2024). Outstanding Young Scientist: Shanghai Society of Biotechnology (2022). 1000 Talent Young Award: CPC Central Committee (2016). Multiple national and international recognitions for cancer research.

Research Focus 🔬

Therapies: Pioneered BCL9/β-catenin inhibitors for colorectal cancer. Immunotherapy: Enhanced T-cell responses and reduced immune resistance. Innovative Molecules: Developed selective inhibitors for challenging pathways. Publications: Authored impactful research in top journals, advancing cancer treatment.

Conclusion

Dr. Di Zhu exemplifies the qualities of a world-class researcher. His groundbreaking contributions to cancer therapy, robust academic output, and numerous accolades strongly support his nomination for the Best Researcher Award, affirming his leadership and innovation in the field of pharmacology and immuno-oncology.

Publication

 

  • Clinical cancer immunotherapy: Current progress and prospects
    Authors: C Liu, M Yang, D Zhang, M Chen, D Zhu
    Journal: Frontiers in Immunology 13, 961805
    Citations: 140 (2022)

 

  • Wnt signaling pathway in cancer immunotherapy
    Authors: Y Zhou, J Xu, H Luo, X Meng, M Chen, D Zhu
    Journal: Cancer Letters 525, 84-96
    Citations: 125 (2022)

 

  • IFNα potentiates anti–PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment
    Authors: B Hu et al., including D Zhu
    Journal: Cancer Discovery 12 (7), 1718-1741
    Citations: 123 (2022)

 

  • The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells
    Authors: DI Zhu et al.
    Journal: Nature Medicine 21 (6), 572-580
    Citations: 116 (2015)

 

  • Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells
    Authors: M Feng et al., including D Zhu
    Journal: Science Advances 5 (5), eaau5240
    Citations: 100 (2019)

 

  • Cyclophilin A and CD147: Novel therapeutic targets for the treatment of COVID-19
    Authors: C Liu, A von Brunn, D Zhu
    Journal: Medicine in Drug Discovery 7, 100056
    Citations: 91 (2020)

 

  • T-cell-based immunotherapy in colorectal cancer
    Authors: M Feng, Z Zhao, M Yang, J Ji, D Zhu
    Journal: Cancer Letters 498, 201-209
    Citations: 67 (2021)

 

  • Targeting the tumor immune microenvironment for cancer therapy in human gastrointestinal malignancies
    Authors: Y Zhang et al., including D Zhu
    Journal: Cancer Letters 458, 123-135
    Citations: 55 (2019)

 

  • Targeting Cyclophilin A and CD147 to Inhibit Replication of SARS-CoV-2 and SARS-CoV-2-Induced Inflammation
    Authors: F Yang et al., including D Zhu
    Journal: Molecular Pharmacology
    Citations: 1 (2023)

 

  • New Approaches Targeting Immuno-oncology and Tumor Microenvironment
    Authors: D Zhu, F He
    Book Chapter: Cancer Treatment: An Interdisciplinary Approach, 63-90
    Citations: 1 (2022)

 

 

 

Abasalt Hosseinzadeh Colagar | Molecular Immunology | Best Researcher Award

Prof. Abasalt Hosseinzadeh Colagar | Molecular Immunology| Best Researcher Award

Prof, University of Mazandaran, Iran

A distinguished molecular biologist with a Ph.D. from Razi University and extensive academic leadership at the University of Mazandaran. Specializing in molecular medicine, genetic diversity, fungal pathogenesis, and plant defenses, I have presented groundbreaking theories and achieved top academic honors. With a track record of pioneering research, I focus on cancer, fertility, and infertility. As Head of the Faculty of Basic Sciences and Nano and Biotechnology Group, I lead innovative research initiatives and mentor future scientists. Committed to advancing biotechnology and molecular biology, I contribute significantly to academia and scientific discourse.🌟

Profile

Scopus

Research Interests 🧬

🔬 Major Field: Molecular Biology and Biotechnology

  • Molecular Medicine: Focus on Cancer, Fertility, and Infertility
  • Molecular Biology: Investigating Genetic Diversity, Molecular Mechanisms of Fungal Pathogenesis, and Plant Defenses
  • Biomedical Engineering: Exploring Plasma Sterilization and Genetic Induction of Microorganisms for Industrial Productions

Educational Records 📚

  • Ph.D. in Molecular and Cell Biology
    Razi University in collaboration with National Institute for Genetic Engineering & Biotechnology (NIGEB), Kermanshah and Tehran, I.R. of Iran
    2000 – 2005

    • GPA: 18.39/20
  • M.Sc. in Molecular and Cell Biology
    Department of Biology, Razi University, Kermanshah, I.R. of Iran
    1997 – 2000

    • GPA: 18.56/20
  • B.Sc. in General Biology
    Department of Biology, Ferdowsi University, Mashhad, I.R. of Iran
    1993 – 1997

    • GPA: 18.24/20

Honors and Awards 🏆

Presented a Global Theory at California Urology Society, selected for initial publication, offering a method for the professional urology community. Beyond the Abstract, First Iranian Ph.D. graduate in Molecular and Cell Biology in I.R. of Iran, Ranked first among 2000 M.Sc. graduates of Molecular and Cell Biology, Razi University, Kermanshah, I.R. of Iran, Ranked first among 1999 M.Sc. Students in science of Razi University, Kermanshah, I.R. of Iran, Ranked first among 1997 B.Sc. graduates of Biology, Ferdowsi University, Mashhad, I.R. of Iran

 

Academic Experience (Career) 👩‍🏫

Professor University of Mazandaran August 2014 – Present Head of Faculty of Basic Sciences University of Mazandaran 2010 – 2013 Head of Nano and Biotechnology Group University of Mazandaran 2006 – Present Head of Central Library and Document Center University of Mazandaran 2007 – Present Assistant Professor University of Mazandaran Sep. 2005 – Nov. 2009 Head of Biology Dept. University of Mazandaran 2006 – 2007 Lecturer Teacher Education Center, Kermanshah, I.R. of Iran 1999 – 2000 Lecturer Emam Ali Primary University Center of Kermanshah, I.R. of Iran 1999 – 2000

Publications Top Notes 📝

  1. Title: Thymoquinone and its therapeutic potentials
    • Journal: Pharmacological Research
    • Year: 2015
    • Volume: 95
    • Pages: 138-158
    • Citations: 508

 

  1. Title: Zinc levels in seminal plasma are associated with sperm quality in fertile and infertile men
    • Journal: Nutrition research
    • Year: 2009
    • Volume: 29
    • Issue: 2
    • Pages: 82-88
    • Citations: 438

 

  1. Title: Zinc is an Essential Element for Male Fertility: A Review of Zn Roles in Men’s Health, Germination, Sperm Quality, and Fertilization
    • Journal: Journal of Reproduction & Infertility
    • Year: 2018
    • Volume: 19
    • Issue: 2
    • Pages: 69-79
    • Citations: 316

 

  1. Title: Ascorbic acid in human seminal plasma: determination and its relationship to sperm quality
    • Journal: Journal of Clinical Biochemistry and Nutrition
    • Year: 2009
    • Volume: 45
    • Issue: 2
    • Pages: 144-149
    • Citations: 171

 

  1. Title: Correlation of sperm parameters with semen lipid peroxidation and total antioxidants levels in astheno-and oligoasheno-teratospermic men
    • Journal: Iranian Red Crescent Medical Journal
    • Year: 2013
    • Volume: 15
    • Issue: 9
    • Pages: 780
    • Citations: 163

 

  1. Title: DNA interaction with Al–N, N′-bis (salicylidene) 2, 2′-phenylendiamine complex
    • Journal: Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
    • Year: 2007
    • Volume: 67
    • Issue: 2
    • Pages: 133
    • Citations: 133

 

  1. Title: Cigarette smoking and the risk of male infertility
    • Journal: Pakistan Journal of Biological Sciences
    • Year: 2007
    • Volume: 10
    • Issue: 21
    • Pages: 3870-4
    • Citations: 104

 

  1. Title: E. coli, P. aeruginosa, and B. cereus bacteria sterilization using afterglow of non-thermal plasma at atmospheric pressure
    • Journal: Applied Biochemistry and Biotechnology
    • Year: 2010
    • Volume: 160
    • Issue: 7
    • Pages: 1978-1984
    • Citations: 88

 

  1. Title: Association of C677T transition of the human methylenetetrahydrofolate reductase (MTHFR) gene with male infertility
    • Journal: Reproduction, Fertility and Development
    • Year: 2016
    • Volume: 28
    • Issue: 6
    • Pages: 786-794
    • Citations: 71

 

  1. Title: Microsatellite (SSR) amplification by PCR usually led to polymorphic bands: Evidence which shows replication slippage occurs in extend or nascent DNA strands
    • Journal: Molecular Biology Research Communications
    • Year: 2016
    • Volume: 5
    • Issue: 3
    • Pages: 167-174
    • Citations: 60

Mi Rim Lee |cancer science Award | Young Scientist Award

Ms. Mi Rim Lee| Genomics Award | Young Scientist Award

👨‍🏫Profile Summary

John Doe is a dedicated Ph.D. candidate in Cancer Biomedical Science at the National Cancer Center Graduate School of Cancer Science and Policy. With a solid academic background in Biomaterials, he obtained both his Master’s and Bachelor’s degrees from Pusan National University. John’s achievements include prestigious scholarships and poster awards from esteemed institutions like the Korean Society of Laboratory Animal Science and the Korean Cancer Association. His research interests lie at the intersection of cancer biology and biomaterials, aiming to contribute novel insights into cancer treatment and therapy development. John’s academic excellence and commitment to cancer research mark him as a promising young scientist in the field.

🌐 Professional Profiles

Education🎓

2019.09~present: National Cancer Center Graduate School of Cancer Science and Policy Major: Cancer Biomedical Science Degree: Ph.D. candidate, 2017.03~2019.02: Pusan National University Major: Biomaterial Degree: MS. 2011.03~2017.02: Pusan National University Major: Biomaterial Degree: BA.

Awards 🏆

2018.02: Title: Scholarship Student Institution: Korean Society of Laboratory Animal Science 2018.07: Title: Poster Award Institution: Korean Society of Laboratory Animal Science 2019.01: Title: Academic Award Institution: College of Life and Resources Sciences, Pusan National University 2021.06: Title: Poster Award Institution: Korean Cancer Associati

📚Top Noted Publication

  1. Title: New Function Annotation of PROSER2 in Pancreatic Ductal Adenocarcinoma
    • Authors: Lee, Y.-S., Im, J., Yang, Y., … Hwang, H., Kim, Y.-H.
    • Journal: Journal of Proteome Research
    • Publication Year: 2024
    • Volume: 23
    • Issue: 3
    • Pages: 905–915

 

  1. Title: Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer
    • Authors: Lee, M.R., Woo, S.M., Kim, M.K., … Kim, Y.-H., Kong, S.-Y.
    • Journal: Cancer Science
    • Publication Year: 2024

 

  1. Title: Complexation of drug and hapten-conjugated aptamer with universal hapten antibody for pancreatic cancer treatment
    • Authors: Choi, S.I., Lee, Y.-S., Lee, Y.M., … Kim, Y.-H., Kim, I.-H.
    • Journal: Journal of Controlled Release
    • Publication Year: 2023
    • Volume: 360
    • Pages: 940–952

 

  1. Title: Refining Classification of Cholangiocarcinoma Subtypes via Proteogenomic Integration Reveals New Therapeutic Prospects
    • Authors: Cho, S.Y., Hwang, H., Kim, Y.-H., … Park, S.-J., Woo, S.M.
    • Journal: Gastroenterology
    • Publication Year: 2023
    • Volume: 164
    • Issue: 7
    • Pages: 1293–1309

 

  1. Title: Establishment of Patient-Derived Organoids Using Ascitic or Pleural Fluid from Cancer Patients
    • Authors: Choi, W., Kim, Y.-H., Woo, S.M., … Lee, K.S., Kong, S.-Y.
    • Journal: Cancer Research and Treatment
    • Publication Year: 2023
    • Volume: 55
    • Issue: 4
    • Pages: 1077–1086

 

  1. Title: Establishment of Patient-derived Preclinical Models for Invasive Papillary Cholangiocarcinoma
    • Authors: Mwesige, B., Lee, M.R., Lee, Y.-S., … Woo, S.M., Kim, Y.-H.
    • Journal: Anticancer Research
    • Publication Year: 2022
    • Volume: 42
    • Issue: 1
    • Pages: 599–608